PEGylated Iron Oxide-gold Core-shell Nanoparticles for Tumor-targeted Delivery of Rapamycin

Overview

Journal 3 Biotech

Publisher Springer

Specialty Biotechnology

Date 2024 Dec 30

PMID 39735611

Authors

Suhana Koothradan

Safia Nayeem

K K Elyas

Affiliations

Soon will be listed here.

Abstract

Rapamycin analogs are approved by the FDA for breast and renal cancer treatment. Hence, the possibility of nanoparticle-mediated delivery of Rapamycin could be examined. In the present study, PEGylated Gold-core shell iron oxide nanoparticles were used for the targeted delivery of Rapamycin, and R-Au-IONPs were formulated. SEM, XRD, and FTIR determined the smooth spherical morphology, and compositional structure, and confirmed the conjugation of Rapamycin onto the NPs. The in vitro drug release study showed a controlled release of the drug over time. R-Au-IONPs showed significant cytotoxicity in MCF 7 cells. Anti-proliferative assays such as trypan blue dye exclusion assay, microscopy, Fluorescent staining, and clonogenic assays were performed. NH staining, Rhodamine 123 staining, PS externalization, and the cleavage of PARP protein by western immunoblot assays confirmed the induction of apoptosis. The mechanism of R-Au-IONP-induced cell death was analyzed by flow cytometry. Our in-vitro study, on the impact of R-Au-IONPs on cell viability in the human breast adenocarcinoma cell line (MCF-7), confirms the efficacy of drug delivery using the nanoparticle system. Further results implied the induction of apoptosis. This drug delivery system using Rapamycin could be a potential candidate in the treatment of breast cancer.

References

Rizvi S, Saleh A . Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018; 26(1):64-70. PMC: 5783816. DOI: 10.1016/j.jsps.2017.10.012. View

Taiti C, Di Sotto A, Stefano G, Percaccio E, Iannone M, Marianelli A . Identification of Volatile Molecules and Bioactivity of Gruyt Craft Beer Enriched with var. L. Essential Oil. Int J Mol Sci. 2024; 25(1). PMC: 10779301. DOI: 10.3390/ijms25010350. View

Liu K, Liu P, Liu R, Wu X . Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med Sci Monit Basic Res. 2015; 21:15-20. PMC: 4332266. DOI: 10.12659/MSMBR.893327. View

Bohn E, Lau T, Wagih O, Masud T, Merico D . A curated census of pathogenic and likely pathogenic UTR variants and evaluation of deep learning models for variant effect prediction. Front Mol Biosci. 2023; 10:1257550. PMC: 10517338. DOI: 10.3389/fmolb.2023.1257550. View

Kari S, Subramanian K, Altomonte I, Murugesan A, Yli-Harja O, Kandhavelu M . Programmed cell death detection methods: a systematic review and a categorical comparison. Apoptosis. 2022; 27(7-8):482-508. PMC: 9308588. DOI: 10.1007/s10495-022-01735-y. View

Di Stefano A . Nanotechnology in Targeted Drug Delivery. Int J Mol Sci. 2023; 24(9). PMC: 10179724. DOI: 10.3390/ijms24098194. View

Leone G, Candido S, Lavoro A, Vivarelli S, Gattuso G, Calina D . Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. Pharmaceutics. 2023; 15(4). PMC: 10142433. DOI: 10.3390/pharmaceutics15041252. View

Dowling R, Topisirovic I, Fonseca B, Sonenberg N . Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2009; 1804(3):433-9. DOI: 10.1016/j.bbapap.2009.12.001. View

Foster K, Fingar D . Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 2010; 285(19):14071-7. PMC: 2863215. DOI: 10.1074/jbc.R109.094003. View

Gousias K, Theocharous T, Simon M . Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma. Biomedicines. 2022; 10(3). PMC: 8945784. DOI: 10.3390/biomedicines10030564. View

Xu Q, Liu S, Gong Q, Zhu R, Liu J, Wu Q . Notch1 Protects against Ischemic-Reperfusion Injury by Suppressing PTEN-Pink1-Mediated Mitochondrial Dysfunction and Mitophagy. Cells. 2023; 12(1). PMC: 9818205. DOI: 10.3390/cells12010137. View

Franken N, Rodermond H, Stap J, Haveman J, van Bree C . Clonogenic assay of cells in vitro. Nat Protoc. 2007; 1(5):2315-9. DOI: 10.1038/nprot.2006.339. View

Liu D . LYN, a Key Gene From Bioinformatics Analysis, Contributes to Development and Progression of Esophageal Adenocarcinoma. Med Sci Monit Basic Res. 2015; 21:253-61. PMC: 4701013. DOI: 10.12659/MSMBR.895463. View

10.

Al-Shabib N, Husain F, Ahmed F, Khan R, Khan M, Ahmad Ansari F . Low Temperature Synthesis of Superparamagnetic Iron Oxide (FeO) Nanoparticles and Their ROS Mediated Inhibition of Biofilm Formed by Food-Associated Bacteria. Front Microbiol. 2018; 9:2567. PMC: 6234955. DOI: 10.3389/fmicb.2018.02567. View

11.

Manjili H, Mamani L, Tavaddod S, Mashhadikhan M, Shafiee A, Naderi-Manesh H . D, L-Sulforaphane Loaded Fe3O4@ Gold Core Shell Nanoparticles: A Potential Sulforaphane Delivery System. PLoS One. 2016; 11(3):e0151344. PMC: 4794166. DOI: 10.1371/journal.pone.0151344. View

12.

Li J, Kim S, Blenis J . Rapamycin: one drug, many effects. Cell Metab. 2014; 19(3):373-9. PMC: 3972801. DOI: 10.1016/j.cmet.2014.01.001. View

12.

Crowley L, Marfell B, Scott A, Boughaba J, Chojnowski G, Christensen M . Dead Cert: Measuring Cell Death. Cold Spring Harb Protoc. 2016; 2016(12). DOI: 10.1101/pdb.top070318. View

13.

Yu Q, Wang S, Zhang Y, Dong Z, Deng H, Guo K . Femtosecond ultrafast pulse generation with high-quality 2H-TaS nanosheets top-down empirical approach. Nanoscale. 2021; 13(48):20471-20480. DOI: 10.1039/d1nr07075d. View

13.

Shi Y, Frankel A, Radvanyi L, Penn L, Miller R, Mills G . Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 1995; 55(9):1982-8. View

14.

Saebo I, Bjoras M, Franzyk H, Helgesen E, Booth J . Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity. Int J Mol Sci. 2023; 24(3). PMC: 9917735. DOI: 10.3390/ijms24032914. View